Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 11/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.38 |
| ▸ | CDK1 | P06493 | 5/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5247935 | 0.86 | PIK3CA (0.44) | PIK3CAJAK3 | |
| SCHEMBL5120764 | 0.85 | AURKA (0.40) | PIK3CAP2RX3AURKACDK1AURKB | |
| SCHEMBL5128100 | 0.84 | CDK1 (0.42) | PIK3CAAURKACDK1AURKB | |
| SCHEMBL5113318 | 0.83 | CDK1 (0.46) | PIK3CAAURKACDK1AURKB | |
| SCHEMBL5119187 | 0.83 | CDK1 (0.46) | PIK3CAAURKACDK1AURKB | |
| SCHEMBL5126819 | 0.81 | CDK4 (0.41) | PIK3CAP2RX3AURKACDK1AURKB | |
| SCHEMBL5128102 | 0.79 | P2RX3 (0.38) | P2RX3AURKACDK1AURKB | |
| SCHEMBL5119191 | 0.79 | CDK4 (0.41) | P2RX3AURKACDK1AURKB | |
| SCHEMBL3339263 | 0.76 | CDK4 (0.44) | PIK3CACDK1 | |
| SCHEMBL5121031 | 0.76 | PIK3CA (0.46) | PIK3CAP2RX3AURKACDK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | claimed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | claimed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | TYMS, DPYD, TYMP | PIK3CA 209/4885P2RX3 32/4885JAK3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.